Temperature-sensitive lyotropic liquid crystals as systems for transdermal drug delivery

Liu, Jinpeng; Cheng, Ranran; Heimann, Kirsten; Wang, Zhongni; Jin-ying, Wang; Liu, Feng

doi:10.1016/j.molliq.2021.115310

Cited by 17 publications

(8 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fusogenic properties [ 72 ], attenuation of P-gp efflux [ 73 ], endosomal escape [ 74 ], and modulation of interactions with lymph node macrophages have been effectively demonstrated for LCNPs [ 75 ]. Furthermore, LCNPs have been engineered to be stimuli-responsive and provide a ligand-targeted therapeutic action at the site of disease [ 76 , 77 , 78 , 79 ]. Modulation of the controlled release of a model hydrophobic substance (clofazimine salt) [ 80 ], and an anticancer agent (PTX) [ 81 ] was shown by lipid cubic phases adjuvanted with a lipase inhibitor, i.e., tetrahydrolipstatin.…”

Section: Pharmacokinetic Modulation Using Lcnpsmentioning

confidence: 99%

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Leu,

Teoh,

Ling

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

Due to their distinctive structural features, lyotropic nonlamellar liquid crystalline nanoparticles (LCNPs), such as cubosomes and hexosomes, are considered effective drug delivery systems. Cubosomes have a lipid bilayer that makes a membrane lattice with two water channels that are intertwined. Hexosomes are inverse hexagonal phases made of an infinite number of hexagonal lattices that are tightly connected with water channels. These nanostructures are often stabilized by surfactants. The structure’s membrane has a much larger surface area than that of other lipid nanoparticles, which makes it possible to load therapeutic molecules. In addition, the composition of mesophases can be modified by pore diameters, thus influencing drug release. Much research has been conducted in recent years to improve their preparation and characterization, as well as to control drug release and improve the efficacy of loaded bioactive chemicals. This article reviews current advances in LCNP technology that permit their application, as well as design ideas for revolutionary biomedical applications. Furthermore, we have provided a summary of the application of LCNPs based on the administration routes, including the pharmacokinetic modulation property.

show abstract

Section: Pharmacokinetic Modulation Using Lcnpsmentioning

confidence: 99%

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Leu,

Teoh,

Ling

et al. 2023

Pharmaceutics

View full text Add to dashboard Cite

show abstract

“…The drug absorption route of transdermal administration can be divided into the transepidermal route and skin appendage route. As the main absorption route, the transepidermal route can be divided into the transcellular route and intercellular route ( Figure 3 ) (Kotla et al., 2017 ). In the transcellular route, the drug needs to pass through the stratum corneum lipid membrane structure, and keratin that filled with highly hydrated cells also limit drug penetration.…”

Section: Transdermal Administrationmentioning

confidence: 99%

Section: Transdermal Administrationmentioning

confidence: 99%

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

et al. 2022

View full text Add to dashboard Cite

Rheumatoid arthritis is a chronic autoimmune disease, with the features of recurrent chronic inflammation of synovial tissue, destruction of cartilage, and bone erosion, which further affects joints tissue, organs, and systems, and eventually leads to irreversible joint deformities and body dysfunction. Therapeutic drugs for rheumatoid arthritis mainly reduce inflammation through regulating inflammatory factors. Transdermal administration is gradually being applied to the treatment of rheumatoid arthritis, which can allow the drug to overcome the skin stratum corneum barrier, reduce gastrointestinal side effects, and avoid the first-pass effect, thus improving bioavailability and relieving inflammation. This paper reviewed the latest research progress of transdermal drug delivery in the treatment of rheumatoid arthritis, and discussed in detail the dosage forms such as gel (microemulsion gel, nanoemulsion gel, nanomicelle gel, sanaplastic nano-vesiclegel, ethosomal gel, transfersomal gel, nanoparticles gel), patch, drug microneedles, nanostructured lipid carrier, transfersomes, lyotropic liquid crystal, and drug loaded electrospinning nanofibers, which provide inspiration for the rich dosage forms of transdermal drug delivery systems for rheumatoid arthritis.

show abstract

“…14,15 At present, LLCs are used as drug delivery systems by all known administration routes. 16 In the case of transdermal systems, the stratum corneum (SC) is the limiting barrier factor. LLCs are highly bioadhesive and stable carriers, which offer advantages over solid lipids, nanoparticles, and liposomes because they favor penetration of molecules through the SC, provide a prolonged release of incorporated substances, and protect them from physical and enzymatic degradation.…”

Section: ■ Introductionmentioning

confidence: 99%

Pluronic P123/DMSO Lyotropic Liquid Crystal for Incorporating Bioactive Substances for Topical Application

Selivanova,

Galeeva,

Ziganshin

et al. 2024

J. Phys. Chem. B

View full text Add to dashboard Cite

Lyotropic liquid crystals (LLCs) have attracted considerably growing interest in drug delivery applications over the last years. The structure of LLC matrices is complementary to cell membranes and provides an efficient, controlled, and selective release of drugs. In this work, a complex of experimental methods was used to characterize binary LLCs Pluronic P123/DMSO and triple LLC systems Pluronic P123/DMSO/Ibuprofen, which are interesting as transdermal drug delivery systems. Liquid crystalline, thermal, and rheological properties of LLCs were studied. Concentration and temperature areas of the lyomesophase existence were found, and phase transition enthalpies were evaluated. Intermolecular interactions among the components were studied by infrared (IR) spectroscopy. In vitro studies of Ibuprofen (Ibu) release from various LLCs allow differentiation of its release depending on the polymer content. Atomic force microscopy and contact angle methods were used to characterize the surface morphology of the hydrophobic membrane, which was used as a stratum corneum model, and also evaluate the adhesion work of the LLCs. A complex analysis of the results provided by these experimental methods allowed revealing correlations between the phase behavior and rheological characteristics of the LLCs and release kinetics of ibuprofen. The proposed biocompatible systems have considerable potential for a transdermal delivery of bioactive substances.

show abstract

Temperature-sensitive lyotropic liquid crystals as systems for transdermal drug delivery

Cited by 17 publications

References 44 publications

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Recent Advances in the Development of Liquid Crystalline Nanoparticles as Drug Delivery Systems

Transdermal delivery of inflammatory factors regulated drugs for rheumatoid arthritis

Pluronic P123/DMSO Lyotropic Liquid Crystal for Incorporating Bioactive Substances for Topical Application

Contact Info

Product

Resources

About